Clinical Trial Update: Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism [Phase 4]

View source ↗

Summary

Phase 4 trial update on standard-dose apixaban after very low-dose thrombolysis for acute intermediate-high risk acute pulmonary embolism; trial terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism
• Pulmonary Embolism Subacute Massive
• Pulmonary Embolism with Acute Cor Pulmonale
• Pulmonary Embolism with Pulmonary Infarction
• Right Ventricular Dysfunction
• Right Ventricular Failure

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Victor Tapson, MD | Conditions: Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism | Phase 4 | Status: TERMINATED | Results posted: 2021-05-18